Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from REPRO-MED Systems ( (KRMD) ) is now available.
REPRO‑MED Systems, a medical device company focused on home infusion therapies, held its 2026 Annual Meeting of Shareholders on May 19, 2026, with 36,678,784 shares voted. Shareholders elected all seven director nominees, including R. John Fletcher and Robert A. Cascella, reinforcing continuity in the company’s board leadership.
Investors also approved an increase in shares available under the 2024 Omnibus Equity Incentive Plan, signaled support for the executive compensation program in an advisory vote, and opted to hold say‑on‑pay votes annually. In addition, shareholders ratified Cherry Bekaert LLP as the independent registered public accountants for the 2026 fiscal year, underscoring broad backing for the company’s governance and compensation framework.
The most recent analyst rating on (KRMD) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on REPRO-MED Systems stock, see the KRMD Stock Forecast page.
Spark’s Take on KRMD Stock
According to Spark, TipRanks’ AI Analyst, KRMD is a Neutral.
The score is held back mainly by still-negative profitability and uneven cash flow despite improving operations and a low-leverage balance sheet. The latest earnings call was a material positive (strong growth, near-breakeven EBITDA, reiterated guidance for positive EBITDA/cash flow), but technicals remain mixed with the stock below key longer-term moving averages and valuation is constrained by ongoing losses.
To see Spark’s full report on KRMD stock, click here.
More about REPRO-MED Systems
Average Trading Volume: 146,421
Technical Sentiment Signal: Buy
Current Market Cap: $183.7M
Learn more about KRMD stock on TipRanks’ Stock Analysis page.